SG11202003625VA - Dual inhibitors of tim-3 and pd-1 pathways - Google Patents

Dual inhibitors of tim-3 and pd-1 pathways

Info

Publication number
SG11202003625VA
SG11202003625VA SG11202003625VA SG11202003625VA SG11202003625VA SG 11202003625V A SG11202003625V A SG 11202003625VA SG 11202003625V A SG11202003625V A SG 11202003625VA SG 11202003625V A SG11202003625V A SG 11202003625VA SG 11202003625V A SG11202003625V A SG 11202003625VA
Authority
SG
Singapore
Prior art keywords
tim
pathways
dual inhibitors
inhibitors
dual
Prior art date
Application number
SG11202003625VA
Other languages
English (en)
Inventor
Pottayil Govindan Nair Sasikumar
Muralidhara Ramachandra
Seetharamaiah Setty Sudarshan Naremaddepalli
Nagaraj Gowda
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of SG11202003625VA publication Critical patent/SG11202003625VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
SG11202003625VA 2017-11-03 2018-10-31 Dual inhibitors of tim-3 and pd-1 pathways SG11202003625VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741039298 2017-11-03
PCT/IB2018/058526 WO2019087087A1 (fr) 2017-11-03 2018-10-31 Double inhibiteurs de voies tim-3 et pd-1

Publications (1)

Publication Number Publication Date
SG11202003625VA true SG11202003625VA (en) 2020-05-28

Family

ID=65033624

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003625VA SG11202003625VA (en) 2017-11-03 2018-10-31 Dual inhibitors of tim-3 and pd-1 pathways

Country Status (14)

Country Link
US (3) US11497734B2 (fr)
EP (1) EP3703683A1 (fr)
JP (2) JP7378394B2 (fr)
KR (1) KR20200083503A (fr)
CN (1) CN111372584A (fr)
AU (1) AU2018360386B2 (fr)
BR (1) BR112020008537A2 (fr)
CA (1) CA3080098A1 (fr)
EA (1) EA202090746A1 (fr)
IL (2) IL274380A (fr)
MX (1) MX2020004531A (fr)
PH (1) PH12020550511A1 (fr)
SG (1) SG11202003625VA (fr)
WO (1) WO2019087087A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2922607C (fr) 2013-09-06 2022-08-30 Aurigene Discovery Technologies Limited Derives 1,2,4-oxadiazole utilises comme immunomodulateurs
WO2016142833A1 (fr) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited Composés 1,2,4-oxadiazoles et thiadiazoles utilisés comme immunomodulateurs
WO2019061324A1 (fr) 2017-09-29 2019-04-04 Curis Inc. Formes cristallines d'immunomodulateurs
EP3694841A1 (fr) 2017-10-11 2020-08-19 Aurigene Discovery Technologies Limited Formes cristallines de 1,2,4-oxadiazole à substitution en position 3
JP7378394B2 (ja) 2017-11-03 2023-11-13 オーリジーン オンコロジー リミテッド Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤
EA202090749A1 (ru) 2017-11-06 2020-08-19 Ориджен Дискавери Текнолоджис Лимитед Способы совместной терапии для иммуномодуляции
CN114286822A (zh) 2019-09-30 2022-04-05 南京明德新药研发有限公司 作为pd-1/pd-l1小分子抑制剂的化合物及其应用
CN114796226B (zh) * 2021-12-17 2023-09-12 新乡医学院 奥拉帕尼在诱导核仁应激中的应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3227725A (en) 1962-04-17 1966-01-04 Union Carbide Corp Certain 3,5-disubstituted 1,2,4-oxadiazole compounds
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
TW201311B (fr) 1991-06-17 1993-03-01 Hoffmann La Roche
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
CA2143246C (fr) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
CA2296080C (fr) 1997-07-29 2005-02-01 Alcon Laboratories, Inc. Compositions ophtalmologiques contenant des polymeres de galactomannan et du borate
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
CA2383456C (fr) 1999-08-23 2016-06-07 Clive Wood Pd-1, recepteur de b7-4, et son utilisation
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
EP1377609B1 (fr) 2001-03-14 2015-06-24 Dako Denmark A/S Nouvelles constructions de molecules mhc, methodes d'utilisation de ces constructions a des fins de diagnostic et de therapie et utilisations de molecules mhc
JP2004533226A (ja) 2001-04-02 2004-11-04 ワイス Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用
WO2002086083A2 (fr) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Procedes d'amelioration de la capacite de reaction de cellules t
JP4488740B2 (ja) 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫細胞活性化を調節する作用剤およびその使用方法
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005014046A2 (fr) 2003-08-07 2005-02-17 Allergan, Inc. Compositions d'administration d'agents therapeutiques dans les yeux et leurs methodes d'elaboration et d'utilisation
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1593671A1 (fr) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG Inhibiteurs de la DPP-IV
JP5065908B2 (ja) 2004-12-24 2012-11-07 プロシディオン・リミテッド Ｇタンパク質結合受容体作動薬
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2006133216A2 (fr) 2005-06-06 2006-12-14 Smithkline Beecham Corporation Composes chimiques
WO2007075749A2 (fr) 2005-12-20 2007-07-05 Merck & Co., Inc. Agonistes du recepteur de la niacine, compositions contenant de tels composes et procedes de traitement
US8748627B2 (en) 2006-02-15 2014-06-10 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2009544625A (ja) 2006-07-20 2009-12-17 メーメット・カーラマン Ｒｈｏキナーゼのベンゾチオフェン阻害剤
AU2007300542B2 (en) 2006-09-25 2012-05-17 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
EP2178531A4 (fr) 2007-07-02 2012-01-11 Yu Ming Méthodes et compositions, cibles pour les traitements combinés du cancer
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
CA2714700C (fr) 2008-02-22 2013-07-30 Irm Llc Composes et compositions heterocycliques comme inhibiteurs de c-kit et pdgfr kinase
WO2010033701A2 (fr) 2008-09-19 2010-03-25 Genzyme Corporation Inhibiteurs de la sphingosine kinase 1
WO2010051447A1 (fr) 2008-10-30 2010-05-06 Elixir Pharmaceuticals, Inc. Composés contenant du sulfamide et leurs utilisations
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
WO2011137587A1 (fr) 2010-05-06 2011-11-10 Hutchison Medipharma Limited Inhibiteurs de cytokines
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN103080134B (zh) 2010-08-20 2015-11-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
WO2012129564A2 (fr) 2011-03-24 2012-09-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibition de chymotrypsine-like du protéasome à l'aide d'analogues de pi-1833
WO2012168944A1 (fr) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Composés thérapeutiques pour une immunomodulation
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
EP2822957A1 (fr) 2012-03-07 2015-01-14 Aurigene Discovery Technologies Limited Composés peptidomimétiques utilisés comme immunomodulateurs
RU2014143443A (ru) 2012-03-29 2016-05-20 Ориджин Дискавери Текнолоджиз Лимитед Иммуномодулирующие циклические соединения
CA2886433C (fr) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
HUE050797T2 (hu) 2012-10-10 2021-01-28 Sangamo Therapeutics Inc T-sejt módosító vegyületek és alkalmazásaik
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014110298A1 (fr) 2013-01-09 2014-07-17 Gilead Sciences, Inc. Hétéroaryles à 5 chaînons et leur utilisation comme agents antiviraux
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
WO2014147586A1 (fr) 2013-03-22 2014-09-25 Novartis Ag 1-(2-(éthylamino)pyrimidin-4-yl)pyrrolidin-2-ones en tant qu'inhibiteurs du mutant idh
AU2014290069B2 (en) 2013-07-16 2019-01-03 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
RU2705795C2 (ru) 2013-08-20 2019-11-12 Мерк Шарп И Доум Корп. Лечение рака комбинацией антагониста pd-1 и динациклиба
CA2922607C (fr) 2013-09-06 2022-08-30 Aurigene Discovery Technologies Limited Derives 1,2,4-oxadiazole utilises comme immunomodulateurs
EP3041828B1 (fr) 2013-09-06 2018-05-23 Aurigene Discovery Technologies Limited Dérivés 1,3,4-oxadiazole et 1,3,4-thiadiazole servant d'immunomodulateurs
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
BR112016010224A2 (pt) 2013-11-05 2018-05-02 Cognate Bioservices, Inc. combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
GB2516515B8 (en) 2013-12-04 2016-10-05 Intelligent Growth Solutions Ltd Automated arrangement to grow plants under lighting in a vertical tower
EP3079699A4 (fr) 2013-12-11 2017-07-19 Glaxosmithkline LLC Traitement du cancer avec une combinaison d'un antagoniste de pd-1 et un inhibiteur de vegfr
DK3087098T3 (da) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista-antistoffer og -fragmenter
JP2016021697A (ja) 2014-07-15 2016-02-04 株式会社日立製作所 通信システム、通信装置、及び、制御装置
WO2016040892A1 (fr) 2014-09-13 2016-03-17 Novartis Ag Polythérapies
EP3200775B1 (fr) 2014-10-03 2019-11-20 Novartis AG Polythérapies
WO2016073470A1 (fr) 2014-11-04 2016-05-12 The University Of Kansas Activateurs de l'ampk de lkb1 pour une utilisation thérapeutique dans la polykystose rénale
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016142833A1 (fr) * 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited Composés 1,2,4-oxadiazoles et thiadiazoles utilisés comme immunomodulateurs
CA2979161A1 (fr) * 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited Composes 3-substitue -1,2,4-oxadiazole et thiadiazole utilises comme immunomodulateurs
KR20170123680A (ko) 2015-03-10 2017-11-08 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서의 1,3,4-옥사다이아졸 및 티아다이아졸 화합물
WO2018047143A1 (fr) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Composés inhibiteurs de la voie de signalisation vista utiles en tant qu'immunomodulateurs
WO2018051254A1 (fr) * 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Composés cycliques substitués -1, 2, 4-oxadiazole en tant qu'immunomodulateurs
CN110139856A (zh) 2016-10-20 2019-08-16 奥列基因发现技术有限公司 Vista和pd-1通路的双重抑制剂
WO2019061324A1 (fr) 2017-09-29 2019-04-04 Curis Inc. Formes cristallines d'immunomodulateurs
EP3694841A1 (fr) 2017-10-11 2020-08-19 Aurigene Discovery Technologies Limited Formes cristallines de 1,2,4-oxadiazole à substitution en position 3
JP7378394B2 (ja) 2017-11-03 2023-11-13 オーリジーン オンコロジー リミテッド Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤
EA202090749A1 (ru) 2017-11-06 2020-08-19 Ориджен Дискавери Текнолоджис Лимитед Способы совместной терапии для иммуномодуляции

Also Published As

Publication number Publication date
CN111372584A (zh) 2020-07-03
BR112020008537A2 (pt) 2020-10-06
CA3080098A1 (fr) 2019-05-09
JP7378394B2 (ja) 2023-11-13
US20200368210A1 (en) 2020-11-26
US20240100024A1 (en) 2024-03-28
IL287959A (en) 2022-01-01
MX2020004531A (es) 2020-08-03
JP2021502965A (ja) 2021-02-04
AU2018360386A1 (en) 2020-05-07
PH12020550511A1 (en) 2021-05-10
US20230062570A1 (en) 2023-03-02
EP3703683A1 (fr) 2020-09-09
WO2019087087A1 (fr) 2019-05-09
EA202090746A1 (ru) 2020-08-17
IL274380A (en) 2020-06-30
JP2023182598A (ja) 2023-12-26
US11497734B2 (en) 2022-11-15
KR20200083503A (ko) 2020-07-08
AU2018360386B2 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
IL287518A (en) Dual inhibitors of the vista and pd-1 pathways
IL262814A (en) Combination treatments of hdac inhibitors and pd-l inhibitors
IL287959A (en) Dual inhibitors of the tim-3 and pd-1 pathways
HK1259232A1 (zh) Menin-mll的取代抑制劑及其使用方法
HK1249513A1 (zh) Kras的稠合三環抑制劑及其使用方法
HK1245677A1 (zh) 用於治療炎症和癌症的雜環itk抑制劑
HK1253276A1 (zh) 使用TGF-β抑制劑和PD-1抑制劑治療癌症
HK1232153A1 (zh) 用於治療癌症的 拮抗劑和 抑制劑的組合
IL254131B (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
EP3684361A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
HK1245247A1 (zh) 溴結構域的抑制劑
ZA201803436B (en) Inhibitors of cxcr2
IL259794A (en) Bicyclic inhibitors for pad4
PL3700902T3 (pl) Inhibitory trpc6
EP3151833A4 (fr) Inhibiteurs de mth1 destinés au traitement des états inflammatoires et auto-immuns
IL279949A (en) Heterocyclic MCT4 inhibitors
IL259796A (en) Aza-benzimidazole inhibitors of pad4
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
EP3265093A4 (fr) Inhibiteurs de kinases tricycliques de melk et procédés d'utilisation
SG11202000621VA (en) Inhibitors of ror?
EP3313403A4 (fr) Traitement du cancer avec des inhibiteurs de dnapk
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
AU2017904351A0 (en) Inhibitors of necroptosis
AU2015903172A0 (en) Inhibitors of necroptosis